aadibio.com - WHWK Operating Margin

Corporate company logo of Aadi Bio (WHWK)

The operating margin visualizes the core operational efficiency of Aadi Bioscience Inc (WHWK), while 0.00 shows the current value of this metric. The oncology base of targeted therapies retains all relevant patients following FDA approval. The patent for rare sarcoma therapy guarantees monopoly status and high profitability. Simultaneously, the company is implementing emission filtration systems, adhering to strict environmental standards.

WHWK: Aadi Bio Profitability of Operations 03/20/2025 - 11/19/2026

WHWK (Aadi Bioscience, Inc.): analytical breakdowns and indicator data

- stock quotes and analyst forecast:
Comprehensive company analysis:Aadi Bio, WHWK
Core merchandise of Aadi Bioscience

Operating margin determines the portion of revenue remaining after deducting all variable and fixed business operating costs, serving as a key indicator of cost management efficiency. An analysis of sales profitability based on operating profit allows for an assessment of the financial stability of Aadi Bioscience Inc (WHWK) within the context of the commercialization of Fyarro and the costs associated with expanding therapeutic indications for the treatment of oncological diseases.

Competitor analysis

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|Operating Profitability CG Oncology Therapeutics CGON|Operating Profit Rate URGN|BCAX: Operating Sales Margin|PSNL: Operating Profitability|Erasca (ERAS) - Operating Profitability|DCTH - Profitability of Operations|YMAB (Y-mAbs Corp) - Operating Margin|Operating Sales Margin Aura Biosciences (AURA)|Operating Profitability Candel Therapeutics Inc. (CADL)|Operating Sales Margin Accuray, Inc. ARAY|Operating Profitability sellaslifesciences.com SLS|Operating Profit Rate ACTU|CTOR - Operating Profitability|Profitability of Operations tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operating Profitability|FATE: Operating Profit Ratio|Operating Sales Margin TCRX|Operating Profitability CSBR|Operating Margin XBIT|Profitability of Operations CEL-SCI Corp.|Operating Profitability ostherapies.com OSTX|RADX: Return on Sales by Operating Profit|ARTV: Operating Sales Margin|ANL (Adlai Nortye) - Return on Sales by Operating Profit|Veru (VERU) - Operating Profitability|Operating Sales Margin Tempest Therapeutics Inc|Operating Profitability Xilio Therapeutics|Return on Sales by Operating Profit RENB (Renovaro Inc.)|Operating Profitability Mural Oncology PLC (MURA)|Operating Margin Kairos Pharma (KAPA)|Operating Profitability onkuretherapeutics.com OKUR|GDTC: Return on Sales by Operating Profit|CRIS: Operating Sales Margin|apollomicsinc.com (APLM) - Operating Sales Margin|THAR: Operating Margin|Operating Sales Margin Advanced Biomed Inc.|Operating Sales Margin GNPX|Return on Sales by Operating Profit CLDI (Calidi Biotherapeutics)|Operating Margin SBFM|Xenetic Biosciences, Inc. - Return on Sales by Operating Profit|Operating Profitability Salarius Pharmaceuticals SLRX|Operating Margin purple-biotech.com PPBT|AONC - Operating Profitability|BGNE: Operating Profitability|CKPT: Operating Margin|Elevation Oncology - Operating Profit Rate|ICAD (iCAD) - Operating Margin|IKNA: Operating Profit Rate|Operating Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin